Tampere, Finland – StemSight Oy, a member of the Platform6 community since May 2022, based in Tampere, is proud to announce the strategic expansion of its leadership team with the appointment of Dr. Ross Macdonald as Chief Commercial Officer. This move signifies StemSight’s commitment to growing its international presence right from Tampere and marks a significant step in their mission to cure corneal blindness through advanced stem cell technology. The company’s expansion and acquisition of new lab space in Kauppi (Finn-Medi), underscore its role as a leader in deep-tech and cutting-edge science.
Dr. Macdonald brings over three decades of pharmaceutical and biopharma industry experience to StemSight, particularly in cell therapy commercialization. His previous role as CEO and Managing Director of Cynata Therapeutics Ltd highlights his successful track record in the field, making him a valuable addition to the Tampere-based team. “I am excited to join StemSight at a time when the company is rapidly advancing its product development pipeline and be involved in the next stage of the company’s growth”, remarks Dr Macdonald.
StemSight’s CEO and founder, Doctor of Technology Laura Koivusalo and Dr Ross Macdonald met at an industry conference, which created the necessary professional connection for future cooperation. Their shared passion to get treatments based on iPS cells into medical use created a bridge between Tampere (Finland) and Melbourne (Australia). “Because the players in the industry develop different types of cells from the same starting material, we are not competitors among ourselves. Instead, everyone openly shares what they have learned about common challenges,” says Dr Koivusalo.
Rooted in groundbreaking science and driven by a mission to heal, StemSight is at the forefront of developing innovative corneal tissue replacements from induced pluripotent stem (iPS) cells. Utilizing the Nobel Prize-winning iPS cell technology, which allows adult cells to be reprogrammed to produce any type of body cell, StemSight specializes in creating various corneal cells. Their unique approach combines corneal cells and biomaterials, setting them apart in the iPS cell-therapy domain. This technology is not just pioneering but also scalable and cost-effective, aimed at providing patients with essential cells lost due to eye diseases.
Supported by Business Finland’s Deep Tech Accelerator pilot funding, StemSight has been able to bring on board top international talent. This support has been instrumental in advancing StemSight’s deep-tech and scientific endeavors while attracting worldwide expertise to Tampere. “StemSight’s commitment to curing blindness with cutting-edge stem cell technology is groundbreaking. The addition of Ross Macdonald to their team marks a critical step in their journey, and we’re eager to see how this influences the future of regenerative medicine,” says Kalle Öhman, Venture Partner at Voima Ventures.
For media inquiries, please contact:
Dr. Laura Koivusalo, CEO of StemSight